Stem cell transplant Patients' fitness under the microscope
NCT ID NCT07049536
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared the physical fitness of 17 people who received an allogeneic stem cell transplant (using donor cells) with healthy volunteers. Researchers measured lung function, muscle strength, balance, and quality of life to see how transplant affects the body. The goal is to better understand fitness levels before and after transplant, which could help guide rehabilitation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better assess and support physical fitness in stem cell transplant patients, potentially improving recovery and quality of life.
- What could go wrong
- This is a small, completed observational study with only 17 participants, so results may not apply to all patients. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
17 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
A total of 30 individuals will be included in the study, consisting of 15 adult patients who have undergone hematopoietic stem cell transplantation and meet the inclusion criteria from the Adult Bone Marrow Transplantation Unit, forming the research group, and 15 healthy individuals forming the control group. RPatients and healthy controls will be matched based on age and gender.The study will commence following Ethics Committee approval and will be conducted in accordance with the principles of the Declaration of Helsinki. Informed consent will be obtained from all participants included in the study.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Currently receiving treatment in the Adult Bone Marrow Transplantation Unit * Between 18 and 65 years of age * Undergoing standard medical treatment including immunosuppressants, antibiotics, and other medications * Clinically stable, able to walk, and cooperative * No history of orthopedic, neurological, or cardiac disorders Exclusion Criteria: * Presence of cognitive impairments * Orthopedic or neurological diseases that may affect the evaluation of physical fitness tests * Presence of facial palsy * Severe visual impairment or visual field defects * Acute bleeding, hemoglobin level ≤ 8 g/dL, and platelet count ≤ 10,000/mm³
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematopoietic stem cell transplantation are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istinye University
Istanbul, 34010, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bone drug plus immune signal stop blood cancer from returning after transplant?
- Can tailored drug dosing make stem cell transplants safer?
- A phone call from a survivor: could peer support calm transplant anxiety?
- Can gut bacteria help rebuild immunity after stem cell transplants?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Could virtual reality help patients recover faster from cell therapy?